The United States Patent and Trademark Office (USPTO) has issued patent US12582635B2 to Biomed Valley Discoveries, Inc. This patent covers novel methods, pharmaceutical compositions, and kits for treating cancers characterized by atypical BRAF mutations (excluding V600E/K mutations) through the use of ERK inhibitors. It also includes methods for identifying patients who would benefit from such therapies.

While this is a patent grant and not a regulatory rule, it signifies a new intellectual property right in the therapeutic area of cancer treatment. Companies operating in oncology drug development, particularly those working with BRAF mutations or ERK inhibitors, should be aware of this granted patent. No immediate compliance actions are required for regulated entities, but it may impact future research, development, and commercialization strategies in this specific cancer treatment niche.